Key Drivers
- Severe liquidity
- Negative equity
- Persistent cash burn
AIAI Summary
MeiraGTx's investment thesis has shifted from clinical upside to an urgent solvency call—cash runway (~$17M) and negative equity make near-term dilutive financing the dominant risk unless the company secures non-dilutive capital or immediately recognizes material deferred revenue. Investors should monitor cash balance, any disclosed ZipBio/licensing proceeds or deferred-revenue recognition timelines, and upcoming financing terms as the primary drivers of upside or near-term collapse.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Severe liquidity
- •Negative equity
- •Persistent cash burn
MGTX faces acute liquidity and solvency stress—cash plunged to $17M, current ratio collapsed to 0.22 and equity turned negative—while continuing heavy operating losses and cash burn despite deferred revenue and tangible assets.
Price Behavior
Key Price Behavior Insights:
- •Mild short-bias
- •Tight range
- •Short-term pullback
Over the last month the stock has traded in a tight range with a mild short-bias (close $7.39 ≈1.5% below the ~$7.50 SMA), recent pullback from $7.81 to $7.39 raising chances of a test of $6.99 support while resistance sits near $7.84.
Quick drop from $7.81 to $7.39 signals short-term weakness
Sentiment & News
Key News Insights:
- •Mixed ratings
- •Modest upside
- •Analyst divergence
MeiraGTx received a "Moderate Buy" consensus on 2026-02-19 but with mixed opinions (2 sell, 4 buy, 1 strong buy), indicating modestly positive yet divergent analyst expectations.
The split analyst outlook suggests limited immediate momentum and likely range-bound trading until clearer corporate catalysts emerge
Similar Companies in Healthcare
Other companies in the same sector with AI ratings